François Dérimay MD, PhD, Gérard Finet MD, PhD, Carlos El Khoury MD, Gilles Rioufol MD, PhD
{"title":"Side Branch Intervention or Not for Non Left Main Provisional Stenting","authors":"François Dérimay MD, PhD, Gérard Finet MD, PhD, Carlos El Khoury MD, Gilles Rioufol MD, PhD","doi":"10.1016/j.jcin.2026.06.029","DOIUrl":"10.1016/j.jcin.2026.06.029","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"19 17","pages":"Page 2428"},"PeriodicalIF":12.7,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148958431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clopidogrel or Aspirin for Long-Term Secondary Prevention in Patients With Diabetes","authors":"Francesco Franchi MD, Fabiana Rollini MD","doi":"10.1016/j.jcin.2026.06.033","DOIUrl":"10.1016/j.jcin.2026.06.033","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"19 17","pages":"Pages 2345-2347"},"PeriodicalIF":12.7,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148961778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hendrianus Hendrianus MD, Diana A. Gorog MD, Udaya S. Tantry PhD, Eliano P. Navarese MD, PhD, Sang Yeub Lee MD, PhD, Jun Hwan Cho MD, Jinhwan Jo MD, Jeonghoon Bae MD, PhD, Sam Yeol Ha MD, PhD, Satoshi Honda MD, PhD, Satoshi Yasuda MD, PhD, Bambang Widyantoro MD, PhD, Sunarya Soerianata MD, Paul A. Gurbel MD, Sang-Wook Kim MD, PhD, Young-Hoon Jeong MD, PhD
{"title":"Ultrashort vs Standard-Duration Dual Antiplatelet Therapy in Acute Coronary Syndrome Patients Undergoing PCI","authors":"Hendrianus Hendrianus MD, Diana A. Gorog MD, Udaya S. Tantry PhD, Eliano P. Navarese MD, PhD, Sang Yeub Lee MD, PhD, Jun Hwan Cho MD, Jinhwan Jo MD, Jeonghoon Bae MD, PhD, Sam Yeol Ha MD, PhD, Satoshi Honda MD, PhD, Satoshi Yasuda MD, PhD, Bambang Widyantoro MD, PhD, Sunarya Soerianata MD, Paul A. Gurbel MD, Sang-Wook Kim MD, PhD, Young-Hoon Jeong MD, PhD","doi":"10.1016/j.jcin.2026.07.012","DOIUrl":"10.1016/j.jcin.2026.07.012","url":null,"abstract":"<div><h3>Background</h3><div>The efficacy and safety of ultrashort (≤1-month) dual antiplatelet therapy (DAPT) followed by antiplatelet monotherapy remain uncertain in acute coronary syndrome (ACS) patients.</div></div><div><h3>Objectives</h3><div>This study sought to compare ultrashort vs standard-duration DAPT in patients with ACS undergoing percutaneous coronary intervention (PCI).</div></div><div><h3>Methods</h3><div>We conducted a systematic review and meta-analysis of randomized controlled trials until February 15, 2026. Primary outcomes were major adverse cardiac and cerebrovascular events (MACCE), major bleeding, and net adverse clinical event (NACE). Prespecified subgroup analyses examined by ethnicity (East Asian vs non-East Asian) and abbreviation strategy (intensive: ≤1-week DAPT or clopidogrel/aspirin monotherapy vs moderate: ≥2-week DAPT, followed by ticagrelor/prasugrel monotherapy).</div></div><div><h3>Results</h3><div>Across 10 trials (n = 29,232), ultrashort DAPT did not increase MACCE risk (HR: 1.06; 95% CI: 0.93-1.20; <em>P</em> = 0.38; <em>I</em><sup>2</sup> = 24%), with higher MACCE risk observed in ST-segment elevation myocardial infarction (STEMI) but not non-ST-segment elevation ACS (NSTE-ACS), and significantly reduced major bleeding (HR: 0.47; 95% CI: 0.35-0.64; <em>P</em> < 0.00001; <em>I</em><sup>2</sup> = 44%), resulting in a net clinical benefit (HR: 0.83; 95% CI: 0.72-0.97; <em>P</em> = 0.02; <em>I</em><sup>2</sup> = 61%). Bleeding reduction was more pronounced in East Asians (HR: 0.35; 95% CI: 0.25-0.49; <em>P</em> < 0.00001; <em>I</em><sup>2</sup> = 0%) than non-East Asians (HR: 0.63; 95% CI: 0.43-0.93; <em>P</em> = 0.02; <em>I</em><sup>2</sup> = 44%), with a significant interaction (<em>P</em> = 0.02). The abbreviation strategy significantly modified outcomes (<em>P</em> for interaction = 0.003): intensive abbreviation raised MACCE risk (HR: 1.37; 95% CI: 1.11-1.69; <em>P</em> = 0.003; <em>I</em><sup>2</sup> = 0%), while moderate abbreviation had no statistically significant difference (HR: 0.96; 95% CI: 0.85-1.08; <em>P</em> = 0.47; <em>I</em><sup>2</sup> = 0%).</div></div><div><h3>Conclusions</h3><div>In patients with ACS undergoing PCI, ultrashort DAPT reduced bleeding without increasing ischemic events overall, although a signal of increased MACCE was observed in STEMI but not in NSTE-ACS. Bleeding reduction was greater in East Asians, while ≤1-week DAPT or clopidogrel/aspirin monotherapy may increase ischemic risk.</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"19 17","pages":"Pages 2311-2329"},"PeriodicalIF":12.7,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148961673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sang Yoon Lee MD, Donghyeon Joo MD, Joo Myung Lee MD, Yong Hwan Park MD, Jong-Young Lee MD, Jin-Ok Jeong MD, Chan Joon Kim MD, Han Cheol Lee MD, Kiyuk Chang MD, Mahn-Won Park MD, Jang-Whan Bae MD, Joon-Hyung Doh MD, Byung Ryul Cho MD, Hee-Yeol Kim MD, Weon Kim MD, Ung Kim MD, Seung-Woon Rha MD, Young Joon Hong MD, Hyun-Jong Lee MD, Sung Gyun Ahn MD, Kyeong Ho Yun MD
{"title":"Clopidogrel vs Aspirin According to Diabetes Mellitus","authors":"Sang Yoon Lee MD, Donghyeon Joo MD, Joo Myung Lee MD, Yong Hwan Park MD, Jong-Young Lee MD, Jin-Ok Jeong MD, Chan Joon Kim MD, Han Cheol Lee MD, Kiyuk Chang MD, Mahn-Won Park MD, Jang-Whan Bae MD, Joon-Hyung Doh MD, Byung Ryul Cho MD, Hee-Yeol Kim MD, Weon Kim MD, Ung Kim MD, Seung-Woon Rha MD, Young Joon Hong MD, Hyun-Jong Lee MD, Sung Gyun Ahn MD, Kyeong Ho Yun MD","doi":"10.1016/j.jcin.2026.05.013","DOIUrl":"10.1016/j.jcin.2026.05.013","url":null,"abstract":"<div><h3>Background</h3><div>Recent trials support the superior efficacy of clopidogrel compared to aspirin monotherapy after completion of dual antiplatelet therapy (DAPT) in patients who have undergone percutaneous coronary intervention (PCI). However, limited evidence is available in patients with diabetes mellitus (DM).</div></div><div><h3>Objectives</h3><div>This study sought to evaluate the comparative efficacy and safety of clopidogrel vs aspirin monotherapy according to the presence of DM.</div></div><div><h3>Methods</h3><div>This was a prespecified analysis of the SMART-CHOICE 3 trial, which was a multicenter, open-label, randomized controlled trial comparing clopidogrel vs aspirin monotherapy in patients with complex coronary lesions or high-risk clinical characteristics. From August 2020 to July 2023, a total of 5,506 patients who underwent PCI and standard DAPT duration and had complex coronary lesions, DM, or previous myocardial infarction, were randomized to clopidogrel or aspirin monotherapy groups. The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE), which was defined as a composite of death from any cause, myocardial infarction, or stroke.</div></div><div><h3>Results</h3><div>Of 5,506 patients, 2,089 had DM (1,039 in the clopidogrel group and 1,050 in the aspirin group). At a median follow-up of 2.3 years (IQR: 1.6-3.0 years), DM patients had a higher risk of MACCE compared to non-DM patients (6.8% vs 4.7%; HR: 1.44, 95% CI: 1.10-1.87; <em>P</em> = 0.008). Clopidogrel showed a significantly lower risk of MACCE than aspirin in DM patients (4.5% vs 9.1%; HR: 0.57, 95% CI: 0.38-0.86; <em>P</em> = 0.008). There was no significant interaction between DM and antiplatelet monotherapy regarding MACCE (<em>P</em> for interaction = 0.124). The risk of bleeding was comparable between the 2 groups in DM patients (2.9% vs 2.9%; HR: 1.06, 95% CI: 0.57-1.95; <em>P</em> = 0.855).</div></div><div><h3>Conclusions</h3><div>Among DM patients who completed the standard duration of DAPT after PCI, clopidogrel monotherapy was associated with a lower risk of a composite of death from any cause, myocardial infarction, and stroke compared with aspirin monotherapy, without increased rates of bleeding. There was no significant interaction between DM and antiplatelet monotherapy with respect to MACCE. (SMART-CHOICE 3 [SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3]; <span><span>NCT04418479</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"19 17","pages":"Pages 2333-2344"},"PeriodicalIF":12.7,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148459802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}